HSBC downgrades Novo Nordisk stock to Hold amid compounding concerns

Published 31/07/2025, 10:22
HSBC downgrades Novo Nordisk stock to Hold amid compounding concerns

Investing.com - HSBC downgraded Novo Nordisk (NYSE:NVO) (NOVOB:DC) from Buy to Hold on Monday, slashing its price target to DKK360.00 from DKK680.00 following the company’s guidance cut.

The downgrade comes after Novo Nordisk reduced its 2025 operating profit guidance by approximately 7% on July 29, with the mid-point of the new guidance range suggesting a mid-single digit exit growth rate for 2025.

HSBC cited the continued illegal selling of weight loss drugs by U.S. compounders despite FDA bans, which has prevented Novo Nordisk from regaining expected market share in the GLP-1 drug market.

The research firm acknowledged its previous Buy rating was incorrect, noting that "our assumption that with FDA’s ban on compounding, Novo might re-gain market share has not played out" and that there are "limited reasons for this situation to change in a short order."

HSBC also raised concerns about whether the consensus GLP market size estimate of over USD120 billion might be significantly overestimated, questioning the safety of medium-term pricing assumptions given the capacity investments in the space.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.